{"id":62638,"date":"2026-04-08T21:04:13","date_gmt":"2026-04-08T13:04:13","guid":{"rendered":"https:\/\/flcube.com\/?p=62638"},"modified":"2026-04-08T21:04:43","modified_gmt":"2026-04-08T13:04:43","slug":"sanofis-bispecific-nanobody-lunsekimig-achieves-primary-endpoints-in-asthma-and-crswnp-phase-ii-studies-shows-mixed-results-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62638","title":{"rendered":"Sanofi&#8217;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong> announced positive top-line results from two Phase II clinical studies of <strong>lunsekimig<\/strong>, a novel bispecific nanobody simultaneously targeting <strong>TSLP and IL-13<\/strong>, demonstrating statistically significant efficacy in <strong>asthma<\/strong> and <strong>chronic rhinosinusitis with nasal polyps (CRSwNP)<\/strong>. However, a third Phase IIb study in <strong>moderate-to-severe atopic dermatitis<\/strong> failed to meet its primary endpoint, though key secondary measures showed promising improvements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-program-overview\">Clinical Program Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Indication<\/th><th>Primary Endpoint<\/th><th>Key Secondary Endpoints<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>AIRCULES<\/strong><\/td><td>Asthma (Phase IIb)<\/td><td>Exacerbation reduction<\/td><td>Lung function improvement<\/td><td><strong>Met<\/strong><\/td><\/tr><tr><td><strong>DUET<\/strong><\/td><td>CRSwNP (Phase IIa)<\/td><td>Nasal polyp score (Week 24)<\/td><td>Nasal congestion score, Lund-Mackay CT score<\/td><td><strong>Met<\/strong><\/td><\/tr><tr><td><strong>VELVET<\/strong><\/td><td>Atopic Dermatitis (Phase IIb)<\/td><td>EASI score improvement<\/td><td>EASI-75, vIGA-AD 0\/1<\/td><td><strong>Not Met<\/strong> (secondary endpoints positive)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bispecific-nanobody-innovation\">Bispecific Nanobody Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Architecture<\/strong>: Five linked antibody fragments (Nanobody VHH format)<\/li>\n\n\n\n<li><strong>Dual Targeting<\/strong>: Simultaneously blocks <strong>TSLP (thymic stromal lymphopoietin)<\/strong> and <strong>IL-13 (interleukin-13)<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses two independent inflammatory drivers contributing to tissue damage in type 2 inflammation diseases<\/li>\n\n\n\n<li><strong>Delivery Advantage<\/strong>: Nanobody format enables enhanced tissue penetration and stability compared to conventional antibodies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-target-validation\">Target Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TSLP Role<\/strong>: Master cytokine upstream regulator of type 2 inflammation cascade<\/li>\n\n\n\n<li><strong>IL-13 Function<\/strong>: Key effector cytokine driving eosinophilic inflammation and tissue remodeling<\/li>\n\n\n\n<li><strong>Synergistic Blockade<\/strong>: Dual inhibition potentially provides superior efficacy versus single-target approaches<\/li>\n\n\n\n<li><strong>Disease Applicability<\/strong>: Relevant across multiple type 2 inflammatory conditions including asthma, CRSwNP, and atopic dermatitis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aircules-phase-iib-asthma-study-results\">AIRCULES Phase IIb Asthma Study Results<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-primary-endpoint-achievement\">Primary Endpoint Achievement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exacerbation Reduction<\/strong>: Statistically significant and clinically meaningful reduction in asthma exacerbations versus placebo<\/li>\n\n\n\n<li><strong>Magnitude of Effect<\/strong>: Specific percentage reduction not disclosed but described as clinically meaningful<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Moderate-to-severe asthma patients with elevated type 2 biomarkers<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-secondary-endpoints\">Key Secondary Endpoints<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lung Function<\/strong>: Significant improvements in FEV1 (forced expiratory volume in 1 second)<\/li>\n\n\n\n<li><strong>Symptom Control<\/strong>: Enhanced asthma control questionnaire (ACQ) scores<\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Improved asthma-related quality of life measures<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Generally well-tolerated with no unexpected safety signals<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-duet-phase-iia-crswnp-study-results\">DUET Phase IIa CRSwNP Study Results<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-primary-endpoint-success\">Primary Endpoint Success<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nasal Polyp Score<\/strong>: Statistically significant improvement from baseline at Week 24 versus placebo<\/li>\n\n\n\n<li><strong>Clinical Relevance<\/strong>: Meaningful reduction in polyp burden with potential for reduced surgical intervention<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-secondary-endpoints-0\">Key Secondary Endpoints<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nasal Congestion\/OBstruction<\/strong>: Significant improvement in patient-reported nasal congestion scores<\/li>\n\n\n\n<li><strong>Radiographic Assessment<\/strong>: Improved Lund-Mackay CT scores indicating reduced sinus inflammation<\/li>\n\n\n\n<li><strong>Endoscopic Evaluation<\/strong>: Enhanced endoscopic appearance scores<\/li>\n\n\n\n<li><strong>Patient-Reported Outcomes<\/strong>: Improved SNOT-22 (Sinonasal Outcome Test) scores<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-velvet-phase-iib-atopic-dermatitis-study-results\">VELVET Phase IIb Atopic Dermatitis Study Results<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-primary-endpoint-miss\">Primary Endpoint Miss<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EASI Score<\/strong>: Failed to achieve statistically significant improvement in percent change from baseline Eczema Area and Severity Index score<\/li>\n\n\n\n<li><strong>Potential Factors<\/strong>: Patient selection, dosing regimen, or disease heterogeneity may have contributed to primary endpoint miss<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-encouraging-secondary-endpoints\">Encouraging Secondary Endpoints<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EASI-75<\/strong>: Statistically significant proportion of patients achieved \u226575% improvement in total EASI score<\/li>\n\n\n\n<li><strong>vIGA-AD 0\/1<\/strong>: Significant proportion achieved completely clear (0) or almost completely clear (1) skin on validated Investigator Global Assessment<\/li>\n\n\n\n<li><strong>Lesion Clearance<\/strong>: Demonstrated meaningful improvement in skin clearance measures despite primary endpoint miss<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Consistent safety profile with other indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-development-pathway\">Strategic Implications &amp; Development Pathway<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-portfolio-prioritization\">Portfolio Prioritization<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asthma Focus<\/strong>: Strong Phase IIb data supports advancement to Phase III development in asthma<\/li>\n\n\n\n<li><strong>CRSwNP Expansion<\/strong>: Positive proof-of-concept data validates expansion into upper airway type 2 inflammation<\/li>\n\n\n\n<li><strong>Atopic Dermatitis Reassessment<\/strong>: May require dose optimization, patient stratification, or combination strategies<\/li>\n\n\n\n<li><strong>Resource Allocation<\/strong>: Likely prioritization of respiratory indications based on robust efficacy signals<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Target Advantage<\/strong>: Unique simultaneous TSLP\/IL-13 blockade differentiates from single-target biologics<\/li>\n\n\n\n<li><strong>Nanobody Platform<\/strong>: Potential for subcutaneous or alternative delivery routes versus intravenous antibodies<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses large patient populations across multiple type 2 inflammatory diseases<\/li>\n\n\n\n<li><strong>Sanofi&#8217;s Inflammation Leadership<\/strong>: Complements existing Dupixent (dupilumab) franchise while offering novel mechanism<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-respiratory-franchise-enhancement\">Respiratory Franchise Enhancement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asthma Market<\/strong>: Potential to capture share from existing biologics with differentiated dual-mechanism approach<\/li>\n\n\n\n<li><strong>CRSwNP Opportunity<\/strong>: Expanding market with limited treatment options beyond surgery and corticosteroids<\/li>\n\n\n\n<li><strong>Cross-Indication Prescribing<\/strong>: Potential for unified treatment approach across upper and lower airway diseases<\/li>\n\n\n\n<li><strong>Pricing Premium<\/strong>: Novel bispecific mechanism supports premium pricing versus single-target therapies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-timeline-expectations\">Development Timeline Expectations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Initiation<\/strong>: Expected to begin in asthma within 12-18 months<\/li>\n\n\n\n<li><strong>CRSwNP Phase IIb<\/strong>: Likely expansion to larger Phase IIb\/III study based on positive Phase IIa data<\/li>\n\n\n\n<li><strong>Atopic Dermatitis Strategy<\/strong>: Potential reformulation or patient selection refinement before further development<\/li>\n\n\n\n<li><strong>Regulatory Pathways<\/strong>: Potential for accelerated approval based on robust Phase IIb asthma data<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context-amp-scientific-significance\">Industry Context &amp; Scientific Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bispecific Trend<\/strong>: Reflects growing industry focus on multi-target approaches for complex inflammatory diseases<\/li>\n\n\n\n<li><strong>Nanobody Validation<\/strong>: Successful clinical proof-of-concept supports nanobody platform for chronic inflammatory conditions<\/li>\n\n\n\n<li><strong>Type 2 Inflammation Evolution<\/strong>: Demonstrates continued innovation in targeting upstream and downstream inflammatory pathways<\/li>\n\n\n\n<li><strong>Precision Medicine<\/strong>: Potential for biomarker-driven patient selection to optimize therapeutic response<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,867,147],"class_list":["post-62638","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62638\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62638\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T13:04:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T13:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis\",\"datePublished\":\"2026-04-08T13:04:13+00:00\",\"dateModified\":\"2026-04-08T13:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638\"},\"wordCount\":798,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62638#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62638\",\"name\":\"Sanofi's Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T13:04:13+00:00\",\"dateModified\":\"2026-04-08T13:04:43+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62638\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62638#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62638","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis","og_description":"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.","og_url":"https:\/\/flcube.com\/?p=62638","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T13:04:13+00:00","article_modified_time":"2026-04-08T13:04:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62638#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62638"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis","datePublished":"2026-04-08T13:04:13+00:00","dateModified":"2026-04-08T13:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62638"},"wordCount":798,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62638#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62638","url":"https:\/\/flcube.com\/?p=62638","name":"Sanofi's Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T13:04:13+00:00","dateModified":"2026-04-08T13:04:43+00:00","description":"Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig, a novel bispecific nanobody simultaneously targeting TSLP and IL-13, demonstrating statistically significant efficacy in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, a third Phase IIb study in moderate-to-severe atopic dermatitis failed to meet its primary endpoint, though key secondary measures showed promising improvements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62638#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62638"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62638#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62638"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62638\/revisions"}],"predecessor-version":[{"id":62640,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62638\/revisions\/62640"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}